Cantor Fitzgerald Reiterates “Hold” Rating for Envision Healthcare (EVHC)

Envision Healthcare (NYSE:EVHC)‘s stock had its “hold” rating reiterated by equities researchers at Cantor Fitzgerald in a report released on Friday, January 5th. They presently have a $37.00 target price on the stock. Cantor Fitzgerald’s price objective points to a potential upside of 3.58% from the company’s current price.

The analysts wrote, “Increasing 2018 estimates and updating PT. We are increasing our 2018 adjusted EPS estimate to $3.95 from $3.40 to reflect a lower corporate tax rate that adds $0.57 to adjusted EPS, offset by changes in the timing and estimated net proceeds from the AMR divestiture, which is now expected to close in 1Q18. Our adjusted 2018 EBITDA estimate remains $982 million, but our new price target reflects higher free cash flow from the lower taxes, and incremental margin improvements from reduced overhead labor costs.””

Other analysts also recently issued research reports about the stock. Robert W. Baird decreased their price target on shares of Envision Healthcare from $70.00 to $35.00 and set an “outperform” rating for the company in a research note on Friday, November 3rd. Zacks Investment Research raised shares of Envision Healthcare from a “strong sell” rating to a “hold” rating in a research note on Tuesday, January 2nd. Oppenheimer decreased their price target on shares of Envision Healthcare from $77.00 to $40.00 and set an “outperform” rating for the company in a research note on Thursday, November 2nd. KeyCorp set a $40.00 price objective on shares of Envision Healthcare and gave the stock a “buy” rating in a research note on Tuesday, November 14th. Finally, Jefferies Group set a $71.00 price objective on shares of Envision Healthcare and gave the stock a “buy” rating in a research note on Wednesday, November 1st. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and nine have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $40.73.

Envision Healthcare (NYSE EVHC) traded down $0.13 on Friday, reaching $35.72. The company had a trading volume of 1,963,612 shares, compared to its average volume of 2,601,863. The company has a current ratio of 3.01, a quick ratio of 3.00 and a debt-to-equity ratio of 0.89. The stock has a market capitalization of $4,333.88, a price-to-earnings ratio of -7.14, a P/E/G ratio of 0.93 and a beta of 0.58. Envision Healthcare has a 12 month low of $23.77 and a 12 month high of $73.00.

Envision Healthcare (NYSE:EVHC) last announced its quarterly earnings data on Tuesday, October 31st. The company reported $0.73 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.81 by ($0.08). The firm had revenue of $1.99 billion during the quarter, compared to the consensus estimate of $2.03 billion. Envision Healthcare had a positive return on equity of 4.88% and a negative net margin of 6.39%. The firm’s revenue for the quarter was up 142.0% on a year-over-year basis. During the same period in the previous year, the business earned $1.13 EPS. analysts predict that Envision Healthcare will post 2.49 earnings per share for the current year.

Envision Healthcare announced that its Board of Directors has authorized a share repurchase plan on Monday, September 18th that authorizes the company to buyback $250.00 million in outstanding shares. This buyback authorization authorizes the company to purchase up to 4.5% of its shares through open market purchases. Shares buyback plans are usually a sign that the company’s board of directors believes its shares are undervalued.

Several institutional investors and hedge funds have recently made changes to their positions in EVHC. Janus Henderson Group PLC grew its holdings in shares of Envision Healthcare by 36,086.8% during the second quarter. Janus Henderson Group PLC now owns 3,945,087 shares of the company’s stock valued at $247,239,000 after buying an additional 3,934,185 shares during the last quarter. OZ Management LP purchased a new stake in shares of Envision Healthcare during the third quarter valued at $131,987,000. Maverick Capital Ltd. lifted its position in Envision Healthcare by 66.2% during the second quarter. Maverick Capital Ltd. now owns 5,093,292 shares of the company’s stock valued at $319,197,000 after purchasing an additional 2,028,026 shares during the period. Lord Abbett & CO. LLC lifted its position in Envision Healthcare by 259.6% during the second quarter. Lord Abbett & CO. LLC now owns 1,321,328 shares of the company’s stock valued at $82,808,000 after purchasing an additional 953,928 shares during the period. Finally, Westfield Capital Management Co. LP acquired a new position in Envision Healthcare during the second quarter valued at $45,892,000.

COPYRIGHT VIOLATION NOTICE: This piece was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another domain, it was stolen and reposted in violation of United States and international copyright and trademark law. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2018/01/13/envision-healthcare-evhc-receives-hold-rating-from-cantor-fitzgerald.html.

About Envision Healthcare

Envision Healthcare Holdings, Inc, formerly CDRT Holding Corporation, is a holding company. The Company, through its subsidiary, provides physician-led medical services in the United States. It operates in two segments: EmCare Holdings, Inc (EmCare) and American Medical Response, Inc (AMR). Its EmCare segment is a provider of integrated facility-based and post-acute care physician services to healthcare facilities in the United States.

Analyst Recommendations for Envision Healthcare (NYSE:EVHC)

Receive News & Ratings for Envision Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envision Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply